The clinical effectiveness of total hip arthroplasty (THA) for the treatment of severe hip pathologies has been widely recognized by the medical community, and over the past 40 years, more patients with hip pathologies have benefited from THA due to advances in surgical techniques and prosthesis design. As a result, more and more research is focused on the development of prosthetic materials to reduce the wear rate of the weight-bearing surface of the prosthesis. A recent systematic evaluation showed that the 5-year survival rate for hard-to-stiff prostheses was higher than 94%, and four of the high-quality randomized controlled studies showed an 8-year survival rate of 96% for vitrified-to-tau prostheses. To date, randomized controlled studies comparing the efficacy of ceramic-to-tau versus ceramic-to-highly cross-linked polyethylene prostheses in patients younger than 61 years of age with total hip replacement are still rare. In this regard, Lauren A et al. conducted a clinical study sponsored by Stryker Canada, which included 92 total hip replacement patients younger than 61 years of age who were randomized to two groups (tau vs. tau vs. polyethylene), which evaluated WOMAC pain, WOMAC function, WOMAC stiffness score, and RAND-12 health status scores were evaluated in the study. The study was published in the latest issue of J Arthroplasty.